fludarabine has been researched along with Lymphoma, Non-Hodgkin in 176 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 48 (27.27) | 18.2507 |
| 2000's | 93 (52.84) | 29.6817 |
| 2010's | 28 (15.91) | 24.3611 |
| 2020's | 7 (3.98) | 2.80 |
| Authors | Studies |
|---|---|
| Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S | 1 |
| Ara, T; Ashida, T; Atsuta, Y; Fukuda, T; Kamijo, K; Kanaya, M; Kim, SW; Kondo, E; Kuriyama, T; Kusumoto, S; Maseki, N; Matsuoka, KI; Mizuno, I; Mizuno, S; Nakazawa, H; Onizuka, M; Shimomura, Y; Shinohara, A; Usui, Y; Yamaguchi, M | 1 |
| Bachanova, V; Bishop, MR; Brower, J; Chen, AI; Devlin, SM; Flynn, JR; Gonen, M; Ip, A; Leslie, LA; Maakaron, J; Maziarz, RT; McGuirk, JP; Nastoupil, LJ; Oluwole, OO; Parascondola, A; Perales, MA; Porter, DL; Riedell, PA; Schuster, SJ; Scordo, M; Shouval, R; Tomas, AA | 1 |
| Ahn, KW; Awan, FT; Chow, VA; Eghtedar, A; Fenske, TS; Hamadani, M; Karmali, R; Khanal, M; Kharfan-Dabaja, MA; Litovich, C; Sauter, C; Winter, A | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA | 1 |
| Slater, H | 1 |
| Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A | 1 |
| Ayala, A; Cabanillas, F; Fanale, MA; Fayad, L; Feng, L; Fowler, NH; Goy, AH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neal, E; Neelapu, SS; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Westin, JR | 1 |
| Chen, B; Gao, C; Ge, Z; Liu, R; Zhang, X | 1 |
| Bay, JO; Blaise, D; Bulabois, CE; Ceballos, P; Chantepie, S; Charbonnier, A; Chevallier, P; Contentin, N; Cornillon, J; Daguindau, E; Deconinck, E; Labopin, M; Le Bourgeois, A; Maillard, N; Marçais, A; Marchand, T; Mercier, M; Mohty, M; N'Guyen, S; Peffault de Latour, R; Rorhlich, PS; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Acharya, UH; Cassaday, RD; Chapuis, AG; Chen, X; Cherian, S; Dhawale, TM; Gauthier, J; Gooley, T; Hawkins, RM; Hay, KA; Hendrie, PC; Hirayama, AV; Kiem, HP; Li, D; Lynch, RC; Maloney, DG; Pender, BS; Ramos, J; Riddell, SR; Shadman, M; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A; Voutsinas, JM; Wu, Q | 1 |
| Berquist, L; Bonavida, B; Chu, P; Clanton, D; Hariharan, K; Ho, SN; Molina, A; Murphy, T; Vega, MI | 1 |
| Azik, F; Emir, S; Erdem, AY; Isik, P; Metin, A; Tavil, B; Tunc, B; Uckan, D | 1 |
| Bartalucci, G; Bocchia, M; Bosi, A; Cencini, E; Dottori, R; Fabbri, A; Gozzetti, A; Puccini, B; Rigacci, L | 1 |
| Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A | 1 |
| Wang, YF; Wang, ZX; Wu, XX; Xu, XX; Yan, B; Yang, HL; Yu, Y; Zhang, YZ; Zhao, DD | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL | 1 |
| Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH | 1 |
| Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF | 1 |
| Annechini, G; Capria, S; D'Elia, GM; De Angelis, F; Foà, R; Pulsoni, A; Russo, E; Stefanizzi, C; Tosti, ME | 1 |
| Berger, C; Chaney, C; Chen, X; Cherian, S; Hanafi, LA; Hawkins, R; Heimfeld, S; Hudecek, M; Li, D; Maloney, DG; Pender, B; Riddell, SR; Robinson, E; Soma, L; Turtle, CJ; Wood, B | 1 |
| van der Griend, R; van der Spek, E | 1 |
| Dumoulin, FL; Fischer, HP; Sauerbruch, T; Wasmuth, JC | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Blazar, BR; Brunstein, CG; Burns, LJ; Cantero, S; Cao, Q; Majhail, N; McClune, B; McGlave, PB; Miller, JS; Tomblyn, M; Wagner, JE; Weisdorf, DJ | 1 |
| Brion, JP; Epaulard, O; Garin-Bastuji, B; Gressin, R; Maurin, M; Meneses, A; Pavese, P; Stahl, JP | 1 |
| Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L | 1 |
| Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A | 1 |
| Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ | 1 |
| Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH | 1 |
| Evangelista, M; Lucotti, S; Patella, F; Rainaldi, G; Rizzo, M | 1 |
| Ansaldi, F; Balleari, E; Bedognetti, D; Boccardo, F; Bruzzone, A; Caltabiano, G; De Maria, A; Durando, P; Ferrarini, M; Icardi, G; Marincola, FM; Massucco, C; Messina, M; Racchi, O; Sertoli, MR; Zanardi, E; Zoppoli, G; Zupo, S | 1 |
| Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Baurmann, H; Bethge, WA; Bornhauser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Stelljes, M; Trenschel, R; Vogel, W; von Harsdorf, S | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Licht, A; Meier, R; Taverna, C; Trojan, A | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Eucker, J; Huhn, D; Jakob, C; Kingreen, D; Mergenthaler, HG; Possinger, K; Schetelig, J; Schille, C; Schmid, P; Sezer, O | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Grenier, JF; Guévin, R; Klasa, RJ; Laplante, S; Maksymiuk, A; Meyer, RM; Rubinger, M; Samosh, M; Sawka, CA; Shustik, C; Smith, A | 1 |
| Cragg, L; Feldman, EJ; Grant, S; Roberts, JD; Smith, MR | 1 |
| Bocchia, M; Forconi, F; Gentili, S; Lauria, F; le Noci, M; Tozzi, M | 1 |
| Dreyling, M; Hiddemann, W; Unterhalt, M | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Bar, M; Cohen, NS; del Prete, S; Flamm, M; Garrett, TJ; Heitjan, D; Hesdorffer, CS; Lonberg, M; March, R; Mears, JG; Nichols, G; Oster, MW; Savage, DG; Talbot, S; Taub, RN | 1 |
| Balcerzak, SP; Chapman, RA; Dakhil, SR; Fisher, RI; Grogan, TM; Lanier, KS; Lew, D; Miller, TP; Spiridonidis, CH; Velasquez, WS | 1 |
| Paschal, BR | 1 |
| Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A | 1 |
| Alliot, C | 1 |
| Disel, U; Paydas, S; Sahin, B; Yavuz, S | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Astrow, AB | 1 |
| Ciancia, R; De Divitiis, B; De Renzo, A; Del Giudice, A; Pane, F; Persico, M; Picardi, M; Quintarelli, C; Rotoli, B; Salvatore, F | 1 |
| Bordonaro, R; Cordio, S; Giannitto-Giorgio, C; Giuffrida, D; Manusia, M; Marletta, F; Novello, G; Petralia, G; Restuccia, N; Salice, P; Serraino, D; Todaro, AM; Ursino, M | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Zinzani, PL | 2 |
| Guan, ZZ; Huang, HQ; Jiang, WQ; Li, XB; Li, YH; Lin, TY; Peng, YL; Sun, XF; Xia, ZJ | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Alinari, L; Baccarani, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Galieni, P; Laszlo, D; Lauria, F; Martinelli, G; Raspadori, D; Tozzi, M | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL | 1 |
| Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
| Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW | 1 |
| Argyrakos, T; Galani, V; Grigoriou, E; Harhalakis, N; Kanavaros, P; Kapsimali, V; Karmiris, T; Naum, C; Nikiforakis, E; Pantelidaki, C; Rontogianni, D; Tsantekidou, M | 1 |
| Boyd, RL; Clyde, J; Halbherr, T; Millenson, MM; Morris, GJ; Padavic-Shaller, K; Rogatko, A; Schilder, RJ; Smith, MR; Wang, H; Yeslow, G | 1 |
| Alam, A; Benyunes, M; Bernstein, SH; Bernstein, ZP; Blumenson, L; Brown, K; Chanan-Khan, A; Czuczman, MS; Donohue, K; Grillo-Lopez, A; Hernandez-Ilizaliturri, F; Klippenstein, D; Koryzna, A; Loud, P; McCarthy, P; Mohr, A; Rock, MK; Skipper, M; Stewart, C | 1 |
| Berthou, C; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Desablens, B; Foussard, C; Ghandour, C; Gressin, R; Lamy, T; Mahé, B; Maisonneuve, H; Pignon, B; Rachieru, P; Rousselet, MC | 1 |
| Gershanovich, ML; Tikhonova, VV | 1 |
| Nichols, GL; Skerrett, DL | 1 |
| Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C | 1 |
| Goor, KM; Huijgens, PC; Schaafsma, MR; van Agthoven, M | 1 |
| Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P | 1 |
| Carter, WH; Cragg, L; Feldman, EJ; Grant, S; Honeycutt, C; Millenson, MM; Murgo, AJ; Padavic-Shaller, K; Ramakrishnan, V; Roberts, JD; Roboz, GJ; Smith, MR; Thune, R | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Gadre, SA; Ge, Y; Lockhart, LH; Northup, JK; Velagaleti, GV | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Anderson, VR; Perry, CM | 1 |
| Antonov, M; Buyukunal, E; Demirkesen, C; Kursunoglu, SG; Ozguroglu, M; Serdaroglu, S; Turna, H; Yanmaz, MT; Yildiz, O | 1 |
| Chitarrelli, I; Fabbri, A; Gobbi, M; Gozzetti, A; Lauria, F; Lenoci, M; Olcese, F; Raspadori, D | 1 |
| Brown, JR; Estrov, Z; Ferrajoli, A; Fiorentino, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Kipps, TJ; Kurzrock, R; Lerner, S; O'Brien, S; Plunkett, W; Ravandi-Kashani, F; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Papageorgiou, S; Psyrri, A; Tsatalas, C; Xiros, N | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Bari, A; Brugiatelli, M; Buda, G; Gobbi, PG; Lazzaro, A; Lombardo, M; Luminari, S; Marcheselli, L; Marcheselli, R; Morabito, F; Pozzi, S; Quarta, G; Sacchi, S; Stelitano, C | 1 |
| Friedberg, JW | 1 |
| Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Hiddemann, W; Pott-Hoeck, C | 2 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE | 1 |
| Bendandi, M; Tura, S; Zinzani, PL | 1 |
| Byrd, JC; Diehl, LF; Hargis, JB; Hospenthal, DR; Kester, KE; Knutson, SW | 1 |
| Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE; Wright, SJ | 1 |
| Cass, Y; Dann, EJ; Gillis, S; Polliack, A; Rochlemer, RR | 1 |
| Catovsky, D; Cunningham, D; Ellis, PA; Emmett, E; Hickish, T; Hill, M; Matutes, E; Mercieca, J; Milan, S; O'Brien, ME | 1 |
| Cheson, BD | 3 |
| Domizio, P; Fearnley, J; Gawler, J; Goldin, J; Johnson, PW; Lister, TA; Nagendran, K; Rohatiner, AZ | 1 |
| Amess, J; Ganjoo, RK; Johnson, PW; Lim, J; Lister, TA; Norton, AJ; Pigaditou, A; Rohatiner, AZ; Rossi, A; Whelan, JS | 1 |
| Engert, A; Freund, M; Gassmann, W; Hiddemann, W; Holtkamp, W; Pott, C; Sandford, D; Seufert, J; Unterhalt, M; Wörmann, B | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| Bendandi, M; Benfenati, D; Bocchia, M; Fanin, R; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL | 1 |
| Ganjoo, R; Johnson, PW; Lister, TA; Rohatiner, AZ; Whelan, JS | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Pawelski, S | 1 |
| Bergmann, L; Diehl, V; Engert, A; Fenchel, K; Hoelzer, D; Mitrou, PS; Pralle, H; Wijermans, P | 1 |
| Falkson, CI | 1 |
| Bosch, F; Briones, J; Colomer, D; Esteve, J; Hadjieu, E; López-Guillermo, A; Montserrat, E; Rozman, C; Urbano-Ispizua, A | 1 |
| Behrens, J; Killick, S; Mercieca, J; Nandi, A | 1 |
| Boscagli, A; Dujardin, P; Gary-Toussain, M; Peyrade, F; Roa, M; Taillan, B | 1 |
| Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL | 1 |
| Hoskin, PJ; Kanegaonkar, R; Mahadevan, A | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Bendandi, M; Benni, M; Cavo, M; de Vivo, A; Magagnoli, M; Rondelli, D; Tura, S; Zamagni, E; Zinzani, PL | 1 |
| Abbondanzo, SL; Aguilera, NI; Byrd, JC; Diehl, LF; Lichy, JH; Shields, DJ | 1 |
| Baccarani, M; Marin, L; Rogato, A; Russo, D; Silvestri, F; Zaja, F | 1 |
| Chapman, R; Grigg, A; Szer, J | 1 |
| Arizpe-Bravo, D; Garcés-Eisele, J; Ponce-de-León, S; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Sánchez-Sosa, S | 1 |
| Leach, M; Parsons, RM; Reilly, JT; Winfield, DA | 1 |
| Catovsky, D; Killick, S; Matutes, E; Sternberg, AJ; Wotherspoon, AC | 1 |
| Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Donato, M; Gajewski, J; Gee, A; Giralt, S; Ippoliti, C; Keating, M; Khouri, IF; Körbling, M; O'Brien, S; Przepiorka, D; Ueno, N; von Wolff, B | 1 |
| Cawley, M; Kaplan, B; Narasihman, P; Taha, HM; Venkatesh, L | 1 |
| Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ | 1 |
| Astori, C; Bernasconi, C; Brusamolino, E; Corso, A; Lazzarino, M; Montillo, M; Morra, E; Orlandi, E; Pagnucco, G; Simoncini, L; Tedeschi, A | 1 |
| Lossos, IS; Paltiel, O; Polliack, A | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Ketterer, N; Moullet, I; Salles, G; Sonet, A; Thieblemont, C | 1 |
| Algeri, R; Bigazzi, C; Bocchia, M; Forconi, F; Lauria, F; Marconcini, S; Marotta, G | 1 |
| Blaschke, V; Braess, J; Brinck, U; Dames, K; Letschert, M; Neumann, C; Reich, K; Rünger, TM; Wörmann, B | 1 |
| Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A | 1 |
| Bennett, JM; Cassileth, PA; Gordon, LI; Hochster, HS; Oken, MM; Raphael, BG; Winter, JN | 1 |
| Bigazzi, C; Bocchia, M; Bucalossi, A; Galieni, P; Laszlo, D; Lauria, F; Marotta, G; Raspadori, D; Scalia, G; Tozzi, M | 1 |
| Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
| Bendandi, M; Cellini, C; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Stefoni, V; Tura, S; Zinzani, PL | 1 |
| Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G | 1 |
| Chim, CS; Liang, R; Wong, SS; Yuen, KY | 1 |
| Ambinder, RF; Byrd, JC; Diehl, LF; Flinn, IW; Grever, MR; Jamison, J; Morrison, C; Murphy, T; Piantadosi, S; Seifter, E; Vogelsang, G | 1 |
| Campbell, S; Ghosh, S; Parker, A; Thomas, R | 1 |
| Galloway, MJ; Hamilton, PJ; Tiplady, CW | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Johnson, SA; Thomas, W | 1 |
| Aul, C; Gattermann, N; Germing, U; Misgeld, E | 1 |
| Baccarani, M; Fanin, R; Patriarca, F; Silvestri, F; Sperotto, A; Zaja, F | 1 |
| Claviez, A; Dreger, P; Glass, B; Humpe, A; Schmitz, N; Schoch, R; Seyfarth, B; Suttorp, M; von Neuhoff, N | 1 |
| Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R | 1 |
| Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J | 1 |
| Bryon, RJ; Chakrabarti, S; Griffiths, MJ; Handa, SK; Milligan, DW | 1 |
| Czuczman, MS | 2 |
| Churn, M; Clough, V | 1 |
| Egerer, G; Ho, AD; Sauerland, K | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 2 |
| Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D | 1 |
| Cabanillas, F; Ford, RJ; Jiang, Y; McLaughlin, P; Medeiros, LJ; Rassidakis, GZ; Sarris, AH; Thomaides, A; Tsimberidou, AM | 1 |
| Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kiamouris, C; Mantzios, G; Nicolaides, C; Papageorgiou, E | 1 |
| Apostolidis, J; Bradburn, M; Cavenagh, JD; Crawley, CR; Foran, JM; Gupta, RK; Leonhardt, M; Lister, TA; Matthews, J; Micallef, IN; Okukenu, E; Rohatiner, AZ; Salam, A; Wiggins, C | 1 |
| Jain, VK; Ogden, JL; Wilder, DD | 1 |
| Abruzzo, LV; Jones, D; Keating, MJ; Luthra, R; Manning, JT; Medeiros, LJ; Rosales, CM; Vega, F | 1 |
| Oken, MM | 1 |
| Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS | 1 |
| Cassileth, PA; Green, MD; Hochster, HS; Kim, KM; Mann, RB; Neiman, RS; O'Connell, MJ; Oken, MM; Ritch, P; Stott, P | 1 |
20 review(s) available for fludarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Lymphoma, Non-Hodgkin; Odds Ratio; Remission Induction; Vidarabine | 2017 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome; Vidarabine | 2004 |
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.
Topics: Adult; Blast Crisis; Bone Marrow Neoplasms; CD4 Antigens; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; In Situ Hybridization; Killer Cells, Natural; Lymphoma, Non-Hodgkin; Male; Neoplasm Invasiveness; RNA, Viral; Skin Neoplasms; Vidarabine | 2004 |
Economic assessment on the management of chronic lymphocytic leukaemia.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Health Care Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Vidarabine | 2005 |
Fludarabine: a review of its use in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine | 2007 |
Fludarabine in the management of malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin; Mycoses; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
The expanding role of fludarabine in hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 1995 |
The role of fludarabine in hematological malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Remission Induction; Vidarabine | 1995 |
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 2000 |
Combination chemotherapy and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Doxorubicin; Flow Cytometry; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Time Factors; Translocation, Genetic; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Humans; Interferon-alpha; Lymphoma, Non-Hodgkin; Multiple Myeloma; Vidarabine | 1992 |
66 trial(s) available for fludarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine | 2021 |
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Interferons; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine; Young Adult | 2017 |
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphocyte Depletion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; Vidarabine | 2019 |
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2015 |
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Topics: Adult; Aged; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphocyte Depletion; Lymphocyte Subsets; Lymphoma, Non-Hodgkin; Male; Middle Aged; Receptors, Antigen, T-Cell; Syndrome; Transgenes; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
Topics: Adolescent; Adult; Aged; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dose-Response Relationship, Radiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radioimmunotherapy; Radiopharmaceuticals; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Yttrium Radioisotopes | 2012 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Vidarabine | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Survival Rate; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Bryostatins; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Vidarabine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2003 |
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Treatment Outcome; United States; Vidarabine | 2003 |
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vidarabine | 2004 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Genes, bcl-2; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; T-Lymphocyte Subsets; Vidarabine | 2005 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Risk Factors; Vidarabine; Vindesine | 2005 |
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Vidarabine | 2006 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Vidarabine | 2007 |
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Research Design; Rituximab; Statistics, Nonparametric; Survival Analysis; Syndrome; Treatment Outcome; Vidarabine | 2008 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2008 |
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome; Vidarabine | 2008 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine | 1995 |
Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
Topics: Adult; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1994 |
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; T-Lymphocytes; Vidarabine | 1994 |
Fludarabine in low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Vidarabine | 1993 |
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Vidarabine | 1993 |
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Vidarabine | 1993 |
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; Humans; Immunosuppression Therapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Survival Analysis; Vidarabine | 1995 |
Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 1996 |
[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine | 1996 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine | 1997 |
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Vidarabine | 1997 |
Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine | 1997 |
Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; CD4 Lymphocyte Count; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1999 |
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine | 2000 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Vidarabine | 2000 |
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine | 2001 |
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Dexamethasone; DNA; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Rituximab; Translocation, Genetic; Vidarabine | 2002 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Vidarabine | 2002 |
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Vidarabine; Vincristine | 2002 |
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate | 1991 |
Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1992 |
91 other study(ies) available for fludarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2022 |
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine | 2023 |
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Recurrence | 2023 |
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Salvage Therapy; Vidarabine | 2020 |
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2017 |
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-1 Antigen; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
Topics: Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neutrophils; Remission Induction; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome | 2013 |
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
[A comparative study of fludarabine-based versus CHOP-like regimens in untreated primary indolent lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Non-Hodgkin; Vidarabine | 2013 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Susceptibility; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; IgG Deficiency; Immunocompromised Host; Immunotherapy; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia; Prednisone; Proportional Hazards Models; Retrospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine; Young Adult | 2015 |
Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
Topics: Aged; Antineoplastic Agents; Databases, Factual; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Neoplasms, Second Primary; Research Design; Sex Factors; Time Factors; Treatment Outcome; Vidarabine | 2008 |
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hepatitis B, Chronic; Humans; Liver; Liver Failure, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2008 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
[Brucella bacteremia reactivation 70 years after the primary infection].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Brucella melitensis; Brucellosis; Combined Modality Therapy; Cyclophosphamide; Doxycycline; Drug Therapy, Combination; Female; France; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Lymphoma, Non-Hodgkin; Recurrence; Rifampin; Rituximab; Spain; Time Factors; Vidarabine | 2010 |
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Vindesine | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult | 2010 |
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine | 2010 |
The RNA activator ds-p21 potentiates the cytotoxicity induced by fludarabine in Dohh2 cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation; Humans; Lymphoma, Non-Hodgkin; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-6; RNA, Double-Stranded; RNA, Messenger; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Case-Control Studies; Female; Humans; Immunoglobulin M; Immunologic Memory; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Lymphoma, Non-Hodgkin; Male; Middle Aged; Orthomyxoviridae; Rituximab; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine | 2011 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Spleen; Syk Kinase; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Aortic Valve Stenosis; Female; Heart Failure; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Middle Aged; Pulmonary Eosinophilia; Vidarabine | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Treatment Outcome; Vidarabine | 2003 |
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Interleukin-2; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prednisone; Recombinant Fusion Proteins; Remission Induction; Rituximab; Time Factors; Vidarabine; Vincristine | 2003 |
Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Social Behavior; Survival; Vidarabine; Vincristine | 2003 |
Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine; Virus Activation | 2003 |
Fludarabine-related myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Flow Cytometry; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Vidarabine | 2003 |
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis C Antibodies; Humans; Lamivudine; Liver Failure; Lymphoma, Non-Hodgkin; Male; Middle Aged; Sequence Homology; Vidarabine; Virus Activation | 2003 |
[Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2004 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; Female; Gastrointestinal Neoplasms; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vidarabine; Vincristine | 2004 |
Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2004 |
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Treatment Outcome; Vidarabine | 2004 |
Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia.
Topics: Antigens, CD34; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Lymphoma: diagnosis, staging, natural history, and treatment strategies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Vidarabine | 2005 |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine | 2005 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 8; Chromosomes, Human, X; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, myc; Humans; Karyotyping; Lymph Nodes; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Mutagenesis, Insertional; Pleural Effusion, Malignant; Prednisone; Rituximab; Translocation, Genetic; Trisomy; Vidarabine; Vincristine | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Paraneoplastic pemphigus associated with fludarabine use.
Topics: Antineoplastic Agents; Humans; Immunoglobulin G; Keratinocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 2007 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
Topics: Antineoplastic Agents; Biopsy; Bronchoscopy; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine | 1995 |
Neurological illness following treatment with fludarabine.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Vidarabine | 1994 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
Treatment of low grade non-Hodgkin's lymphomas with fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 1993 |
Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma.
Topics: Acute Disease; Aged; Humans; Lymphoma, Non-Hodgkin; Male; Renal Dialysis; Tumor Lysis Syndrome; Vidarabine | 1997 |
[A nidulans bronchial aspergillosis after treatment of low-grade lymphoma with fludarabine].
Topics: Antineoplastic Agents; Aspergillosis; Bronchial Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Vidarabine | 1997 |
Third space sequestration increases toxicity of fludarabine--a case report.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drainage; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion; Sepsis; Vidarabine | 1997 |
Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Viral; Antineoplastic Agents; CD4 Lymphocyte Count; Cell Transformation, Neoplastic; DNA Primers; Female; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Vidarabine; Viral Matrix Proteins | 1997 |
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine | 1997 |
Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Drug Synergism; Female; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Pneumonia, Viral; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Vincristine; Viral Load | 1998 |
Tuberculosis-associated fatal hemophagocytic syndrome in a patient with lymphoma treated with fludarabine.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Tuberculosis; Vidarabine | 1998 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney Calculi; Kidney Diseases; Kidney Tubules; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oliguria; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 1998 |
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 1998 |
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Enhancement, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 1998 |
Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Humans; Immunosuppressive Agents; Incidence; Infection Control; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Retrospective Studies; Vidarabine | 1998 |
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Vidarabine; Vincristine | 1998 |
Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vidarabine | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 1999 |
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine | 1999 |
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus.
Topics: Adult; CD8-Positive T-Lymphocytes; Drug Eruptions; Epidermis; Female; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Immunophenotyping; Immunosuppressive Agents; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Lymphoma, Non-Hodgkin; Pemphigus; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 1999 |
The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Viral; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Opportunistic Infections; Vidarabine; Virus Activation | 1999 |
Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Vidarabine | 2000 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2000 |
Cryptococcal infection associated with fludarabine therapy.
Topics: Antineoplastic Agents; CD4-CD8 Ratio; Cryptococcosis; Fatal Outcome; Fungemia; Humans; Immunocompromised Host; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |
Fludarabine induced intestinal pseudo-obstruction: case report and literature review.
Topics: Aged; Antineoplastic Agents; Humans; Intestinal Pseudo-Obstruction; Lymphoma, Non-Hodgkin; Male; Radiography; Vidarabine | 2000 |
Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine.
Topics: Antineoplastic Agents; Autoantibodies; Autoimmunity; Contusions; Hemophilia A; Hemorrhage; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2001 |
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
Topics: Adult; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Recombinant Proteins; Remission Induction; Time Factors; Vidarabine | 2001 |
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenograstim; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nuclear Family; Psoriasis; Recombinant Proteins; T-Lymphocyte Subsets; Transplantation Chimera; Vidarabine | 2001 |
Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Vidarabine | 2001 |
Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cyclophosphamide; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Pancytopenia; Prednisone; Red-Cell Aplasia, Pure; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2001 |
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2002 |
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine | 2000 |
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Ribosomal Proteins; RNA-Binding Proteins; Vidarabine | 2002 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |